Answers are grounded in this paper and cite their sources.
In pediatric chronic kidney disease (CKD), uremic solute measurements are interpreted during growth and maturation, when both exposure and clinically relevant outcomes may change. This narrative review examines indoxyl sulfate (IS), p-cresyl sulfate (pCS), and β2-microglobulin across CKD stages and treatment settings. Pediatric studies report solute-specific retention before dialysis. In the 4C cohort, total IS was associated with CKD progression and selected vascular measures, whereas corresponding adjusted associations were not established for pCS. A longitudinal pediatric study linked total IS with lower height velocity at ages 2–12 years. The association was small and requires independent replication with direct assessment of pubertal stage. Neurocognitive findings vary by metabolite and test. Hemodiafiltration findings depend on whether the endpoint is intradialytic removal or sustained predialysis concentration. Differences in sampling, measured fractions, and cohort membership limit comparisons with adult studies. The research priority is to determine whether repeated, standardized measurements add early prognostic information beyond established clinical markers and whether acting on that information improves growth, kidney health, or other outcomes relevant to children. Clinical thresholds and benefit from IS- or pCS-guided care have yet to be established.
No takes yet. Share an insight, caveat, or question.
Dotis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: